

Company registration number: 651042

Smart Health Direct Limited
Unaudited abridged financial statements
for the financial year ended 31 August 2025

Smart Health Direct Limited

Contents

	Page
Directors responsibilities statement	1
Balance sheet	2 - 3
Notes to the abridged financial statements	4 - 11

Smart Health Direct Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements as set out on pages 4 to 11.

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to Milne O'Dwyer Chartered Accountants, the company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 31 August 2025.

On behalf of the board

Tom Quinn
Director

Cathy Quinn
Director

Date: 26 January 2026

Smart Health Direct Limited

**Balance sheet
As at 31 August 2025**

		2025		2024	
	Note	€	€	€	€
Fixed assets					
Intangible assets	6	630,000		-	
Tangible assets	7	2,016,000		-	
			2,646,000		-
Current assets					
Debtors	8	15,151		100	
Cash at bank and in hand		399,678		-	
			414,829	100	
Creditors: amounts falling due within one year					
	9	(41,000)		-	
Net current assets			373,829		100
Total assets less current liabilities			3,019,829		100
Provisions for liabilities	10	(250,470)			-
Net assets			2,769,359		100
Capital and reserves					
Called up share capital presented as equity	12	946,987		100	
Share premium account		1,555,140		-	
Profit and loss account		267,232		-	
Shareholders funds			2,769,359		100

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 4 to 11 form part of these abridged financial statements.

Smart Health Direct Limited

**Balance sheet (continued)
As at 31 August 2025**

We, as directors of Smart Health Direct Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- the company qualifies for the small companies regime on the grounds that section 280C of the Companies Act 2014 is complied with and the financial statements have been prepared in accordance with the small companies regime;
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 26 January 2026 and signed on behalf of the board by:

Tom Quinn
Director

Cathy Quinn
Director

The notes on pages 4 to 11 form part of these abridged financial statements.

Smart Health Direct Limited

Notes to the abridged financial statements Financial year ended 31 August 2025

1. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention and comply with the accounting standards issued by the Financial Reporting Council, specifically Financial Reporting Standard 102 - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (FRS 102) as adapted by Section 1A of FRS 102 and with the Companies Act 2014.

Functional Currency

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Smart Health Direct Limited's turnover derives from childcare fees and childcare schemes funded by Pobal both of which are exempt from VAT.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Goodwill - 10 % straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Smart Health Direct Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Freehold property	- 4%	straight line
-------------------	------	---------------

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates. For this company cost is used for depreciation.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Smart Health Direct Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Cash at bank and in hand

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the balance sheet and the amount of the provision as an expense.

Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Smart Health Direct Limited

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

Smart Health Direct Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025

2. Operating profit

Operating profit is stated after charging/(crediting):

	2025	2024
	€	€
Amortisation of intangible assets	70,000	-
Depreciation of tangible assets	84,000	-
	84,000	-

3. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 28 (2024: -).

The aggregate payroll costs incurred during the financial year were:

	2025	2024
	€	€
Wages and salaries	854,232	-
Social insurance costs	85,046	-
Other retirement benefit costs	2,379	-
	941,657	-

4. Directors remuneration

The directors aggregate remuneration was as follows:

	2025	2024
	€	€
Emoluments in respect of qualifying services	87,723	-
Pension contributions to defined contribution plans in respect of qualifying services	2,379	-
	90,102	-

5. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	-	-
Profit for the financial year	267,232	-
At the end of the financial year	267,232	-

Smart Health Direct Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025

6. Intangible assets	Goodwill	Total
	€	€
Cost		
At 1 September 2024	-	-
Additions	700,000	700,000
At 31 August 2025	<u>700,000</u>	<u>700,000</u>
Amortisation		
At 1 September 2024	-	-
Charge for the financial year	70,000	70,000
At 31 August 2025	<u>70,000</u>	<u>70,000</u>
Carrying amount		
At 31 August 2025	<u>630,000</u>	<u>630,000</u>
At 31 August 2024	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>
7. Tangible assets	Freehold property	Total
	€	€
Cost		
At 1 September 2024	-	-
Additions	2,100,000	2,100,000
Disposals	-	-
At 31 August 2025	<u>2,100,000</u>	<u>2,100,000</u>
Depreciation		
At 1 September 2024	-	-
Charge for the financial year	84,000	84,000
At 31 August 2025	<u>84,000</u>	<u>84,000</u>
Carrying amount		
At 31 August 2025	<u>2,016,000</u>	<u>2,016,000</u>
At 31 August 2024	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>

Smart Health Direct Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025

8. Debtors	2025	2024
	€	€
Trade debtors	10,426	-
Prepayments	4,725	100
	<u>15,151</u>	<u>100</u>
	<u><u>15,151</u></u>	<u><u>100</u></u>
9. Creditors: amounts falling due within one year	2025	2024
	€	€
Amounts owed to credit institutions	32	-
Other creditors including tax and social insurance	38,983	-
Accruals	1,985	-
	<u>41,000</u>	<u>-</u>
	<u><u>41,000</u></u>	<u><u>-</u></u>
10. Provisions	2025	2024
	€	€
Deferred tax	250,470	-
	<u>250,470</u>	<u>-</u>
	<u><u>250,470</u></u>	<u><u>-</u></u>
11. Government grants	2025	2024
	€	€
At the start of the financial year	-	-
Grants received or receivable	1,057,571	-
Grants repaid	-	-
Released to profit or loss	(1,057,571)	-
	<u>-</u>	<u>-</u>
At the end of the financial year	<u><u>-</u></u>	<u><u>-</u></u>
12. Share capital		

Smart Health Direct Limited

**Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025**

Share movements

	Number	€
At 1 September 2024	100	100
Issue of shares	946,888	946,888
	946,988	946,988
At 31 August 2025	946,988	946,988

13. Events after the end of the reporting period

There are no post balance sheet events.

14. Directors transactions

During the financial year the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	2025	2024
	€	€
At the start of the financial year	-	-
Advances made during the financial year	5,100	-
Amounts repaid during the financial year	(5,560)	-
	(460)	-
At the end of the financial year	(460)	-

Disclosure for each director or other person is as follows:

Tom Quinn

	2025	2024
	€	€
At the start of the financial year	-	-
Advances made during the financial year	5,100	-
Amounts repaid during the financial year	(5,560)	-
	(460)	-
At the end of the financial year	(460)	-

This loan is interest free and repayable on demand.

15. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 26 January 2026.